Laboratory Investigation of Thrombophilia: The Good, the Bad, and the Ugly

ABSTRACT

Thrombophilia can be broadly defined as an increased tendency toward hypercoagulability and venous thrombosis. There are several defined risk factors for thrombosis, and these are generally distinguished as either acquired or congenital, although sometimes this distinction is blurred because of interrelationships. Congenital risk factors include deficiencies or defects in natural anticoagulants, such as antithrombin, Protein C and Protein S, and genetic polymorphisms such as prothrombin G20210A and cleavage-resistant forms of factor V (in particular factor V Leiden), that lead to a condition commonly known as activated protein C resistance. Acquired risk factors include antiphospholipid antibodies, detected as lupus anticoagulants and/or anticardiolipin antibodies and/or anti-β-2-glycoprotein-I antibodies. High levels of clotting factors, dysfibrinogenemia, hyperhomocysteinemia, prolonged immobilization, increasing age, surgery, trauma, cancer, obesity, poor nutrition, pregnancy, oral contraceptives, and hormone replacement therapy comprise just some of the other risk factors. Each of these elements constitutes a component of increased risk, which is compounded when concomitant. There is ongoing debate regarding relative and compound risks, the value of laboratory screening, whom and when to screen for these markers, which tests and methodologies to use, and the form and duration of therapeutic management. The current article explores several important issues primarily from a scientific perspective and predominantly related to laboratory testing. Many of these issues appear to be simply overlooked by some clinicians managing patients with thromboses. In brief, although there is potential significance in testing for various thrombophilia-associated markers, this value is limited and greatly diminishes when inappropriately applied. The application of excessive or inappropriate thrombophilia testing is of particular concern, and the net effect of current worldwide testing trends is likely to be more detrimental than beneficial. In short, it is likely that current generalized testing is simply doing more harm than good, and thus that ordering practice requires scrutiny.

KEYWORDS

Thrombophilia - diagnosis - laboratory testing - protein C - protein S - antithrombin - activated protein C resistance - lupus anticoagulant - antiphospholipid antibodies

REFERENCES

• 1 Mannucci P M. Laboratory detection of inherited thrombophilia: a historical perspective.  Semin Thromb Hemost. 2005;  31(1) 5-10
• 2 Tripodi A. A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia.  Semin Thromb Hemost. 2005;  31(1) 25-32
• 3 Hertzberg M S. Genetic testing for thrombophilia mutations.  Semin Thromb Hemost. 2005;  31(1) 33-38
• 4 Favaloro E J. Diagnostic issues in thrombophilia: a laboratory scientist's view.  Semin Thromb Hemost. 2005;  31(1) 11-16
• 5 Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over.  Semin Thromb Hemost. 2008;  34(8) 747-761
• 6 Varga E A, Kerlin B A, Wurster M W. Social and ethical controversies in thrombophilia testing and update on genetic risk factors for venous thromboembolism.  Semin Thromb Hemost. 2008;  34(6) 549-561
• 7 Cohn D M, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing.  Semin Thromb Hemost. 2007;  33(6) 573-581
• 8 Coppola A, Tufano A, Cerbone A M, Di Minno G. Inherited thrombophilia: implications for prevention and treatment of venous thromboembolism.  Semin Thromb Hemost. 2009;  35(7) 683-694
• 9 Rosendaal F R, Reitsma P H. Genetics of venous thrombosis.  J Thromb Haemost. 2009;  7(Suppl 1) 301-304
• 10 de Moerloose P, Neerman-Arbez M. Congenital fibrinogen disorders.  Semin Thromb Hemost. 2009;  35(4) 356-366
• 11 Wong R C, Favaloro E J. Clinical features, diagnosis, and management of the antiphospholipid syndrome.  Semin Thromb Hemost. 2008;  34(3) 295-304
• 12 Adams M, Palatinus A. Thrombosis in systemic lupus erythematosus.  Semin Thromb Hemost. 2009;  35(7) 621-629
• 13 Galli M, Barbui T. Antiphospholipid syndrome: clinical and diagnostic utility of laboratory tests.  Semin Thromb Hemost. 2005;  31(1) 17-24
• 14 Galli M. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome.  Semin Thromb Hemost. 2008;  34(4) 329-334
• 15 Favaloro E J, Wong R C. Antiphospholipid antibodies and the antiphospholipid syndrome II: limitations, standardization, and clinical utility of laboratory testing.  Semin Thromb Hemost. 2008;  34(4) 309-312
• 16 Oku K, Atsumi T, Amengual O, Koike T. Antiprothrombin antibody testing: detection and clinical utility.  Semin Thromb Hemost. 2008;  34(4) 335-339
• 17 Pierangeli S S, Harris E N. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is?.  Semin Thromb Hemost. 2008;  34(4) 313-328
• 18 Falanga A. Thrombophilia in cancer.  Semin Thromb Hemost. 2005;  31(1) 104-110
• 19 Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment.  Semin Thromb Hemost. 2008;  34(3) 282-285
• 20 Allman-Farinelli M A, Dawson B. Diet and aging: bearing on thrombosis and hemostasis.  Semin Thromb Hemost. 2005;  31(1) 111-117
• 21 Brand-Miller J, Dickinson S, Barclay A, Allman-Farinelli M. Glycemic index, glycemic load, and thrombogenesis.  Semin Thromb Hemost. 2009;  35(1) 111-118
• 22 Gallus A S. Travel, venous thromboembolism, and thrombophilia.  Semin Thromb Hemost. 2005;  31(1) 90-96
• 23 Hoffman R, Brenner B. Thrombophilia related issues in women and children.  Semin Thromb Hemost. 2005;  31(1) 97-103
• 24 Grandone E, Tomaiuolo M, Colaizzo D, Ames P RJ, Margaglione M. Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy.  Semin Thromb Hemost. 2009;  35(7) 630-643
• 25 Tincani A, Bazzani C, Zingarelli S, Lojacono A. Lupus and the antiphospholipid syndrome in pregnancy and obstetrics: clinical characteristics, diagnosis, pathogenesis, and treatment.  Semin Thromb Hemost. 2008;  34(3) 267-273
• 26 Franchini M, Mannucci P M. Von Willebrand factor: another Janus-faced hemostasis protein.  Semin Thromb Hemost. 2008;  34(7) 663-669
• 27 Bucek R A, Reiter M, Quehenberger P, Weltermann A, Kyrle P A, Minar E. Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?.  Br J Haematol. 2003;  120(1) 123-128
• 28 Pierangeli S S, Chen P P, Raschi E et al.. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms.  Semin Thromb Hemost. 2008;  34(3) 236-250
• 29 Lippi G, Franchini M, Favaloro E J. Coagulopathies and thrombosis: usual and unusual causes and associations, Part II.  Semin Thromb Hemost. 2009;  35(7) 591-598
• 30 Cohn D M, Vansenne F, Kaptein A A, De Borgie C A, Middeldorp S. The psychological impact of testing for thrombophilia: a systematic review.  J Thromb Haemost. 2008;  6(7) 1099-1104
• 31 Martinelli I. Pros and cons of thrombophilia testing: pros.  J Thromb Haemost. 2003;  1(3) 410-411
• 32 Machin S J. Pros and cons of thrombophilia testing: cons.  J Thromb Haemost. 2003;  1(3) 412-413
• 33 Martinelli I. Rebuttal to: pros and cons of thrombophilia testing—cons.  J Thromb Haemost. 2003;  1(6) 1311-1312
• 34 Lane D A, Mannucci P M, Bauer K A et al.. Inherited thrombophilia: Part 2.  Thromb Haemost. 1996;  76(6) 824-834
• 35 Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology . Investigation and management of heritable thrombophilia.  Br J Haematol. 2001;  114(3) 512-528
• 36 Van Cott E M, Laposata M, Prins M H. Laboratory evaluation of hypercoagulability with venous or arterial thrombosis.  Arch Pathol Lab Med. 2002;  126(11) 1281-1295
• 37 De Stefano V, Rossi E, Paciaroni K, Leone G. Screening for inherited thrombophilia: indications and therapeutic implications.  Haematologica. 2002;  87(10) 1095-1108
• 38 Kamphuisen P W, Rosendaal F R. Thrombophilia screening: a matter of debate.  Neth J Med. 2004;  62(6) 180-187
• 39 Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients?.  Br J Haematol. 2008;  143(3) 321-335
• 40 Simioni P, Prandoni P, Lensing A W et al.. The risk of recurrent venous thromboembolism in patients with an Arg506—>Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med. 1997;  336(6) 399-403
• 41 De Stefano V, Martinelli I, Mannucci P M et al.. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med. 1999;  341(11) 801-806
• 42 Makris M, Rosendaal F R, Preston F E. Familial thrombophilia: genetic risk factors and management.  J Intern Med Suppl. 1997;  740 9-15
• 43 Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S.  Blood. 1995;  85(12) 3518-3523
• 44 Nowak-Göttl U, Junker R, Kreuz W Childhood Thrombophilia Study Group et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors.  Blood. 2001;  97(4) 858-862
• 45 Lippi G, Favaloro E J, Franchini M. Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside.  Semin Thromb Hemost. 2009;  35(1) 3-8
• 46 Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.  Lancet. 2003;  362(9383) 523-526
• 47 Christiansen S C, Cannegieter S C, Koster T, Vandenbroucke J P, Rosendaal F R. Thrombophilia, clinical factors, and recurrent venous thrombotic events.  JAMA. 2005;  293(19) 2352-2361
• 48 Ho W K, Hankey G J, Quinlan D J, Eikelboom J W. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.  Arch Intern Med. 2006;  166(7) 729-736
• 49 Marchiori A, Mosena L, Prins M H, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.  Haematologica. 2007;  92(8) 1107-1114
• 50 Segal J B, Brotman D J, Necochea A J et al.. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review.  JAMA. 2009;  301(23) 2472-2485
• 51 Coppens M, Reijnders J H, Middeldorp S, Doggen C J, Rosendaal F R. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis.  J Thromb Haemost. 2008;  6(9) 1474-1477
• 52 Eichinger S, Pabinger I, Stümpflen A et al.. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.  Thromb Haemost. 1997;  77(4) 624-628
• 53 Kearon C. Initial treatment of venous thromboembolism.  Thromb Haemost. 1999;  82(2) 887-891
• 54 Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.  Thromb Haemost. 1999;  81(5) 684-689
• 55 Ridker P M, Goldhaber S Z, Danielson E PREVENT Investigators et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.  N Engl J Med. 2003;  348(15) 1425-1434
• 56 Favaloro E J, Soltani S, McDonald J, Grezchnik E, Easton L. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO-blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis.  Lab Hematol. 2005;  11(3) 174-184
• 57 Favaloro E J, Bonar R, Sioufi J et al.. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.  Semin Thromb Hemost. 2005;  31(1) 49-58
• 58 Meijer P, Haverkate F. External quality assessment and the laboratory diagnosis of thrombophilia.  Semin Thromb Hemost. 2005;  31(1) 59-65
• 59 Jennings I, Kitchen S, Woods T A, Preston F E. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program.  Semin Thromb Hemost. 2005;  31(1) 66-72
• 60 Favaloro E J, Bonar R. Emerging technologies and quality assurance in hemostasis: a review of findings from the Royal College of Pathologists of Australasia Quality Assurance Program.  Semin Thromb Hemost. 2007;  33(3) 235-242
• 61 Favaloro E J. Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process.  Semin Thromb Hemost. 2005;  31(1) 85-89
• 62 Preston F E, Kitchen S, Jennings I, Woods T AA. A UK National External Quality Assessment scheme (UK Neqas) for molecular genetic testing for the diagnosis of familial thrombophilia.  Thromb Haemost. 1999;  82(5) 1556-1557
• 63 Hertzberg M, Neville S, Favaloro E, McDonald D. External quality assurance of DNA testing for thrombophilia mutations.  Am J Clin Pathol. 2005;  123(2) 189-193
• 64 Lutz C T, Foster P A, Noll W W et al.. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.  Clin Chem. 1998;  44(6 Pt 1) 1356-1358
• 65 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations—a cause for concern.  Thromb Haemost. 2002;  88(4) 690-691
• 66 Favaloro E J, Wong R CW, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing.  Semin Thromb Hemost. 2005;  31(1) 73-84
• 67 Favaloro E J, Wong R C. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: a potpourri of problems, a compilation of possible solutions.  Semin Thromb Hemost. 2008;  34(4) 389-410
• 68 Montagnana M, Favaloro E J, Franchini M, Guidi G C, Lippi G. The role of ethnicity, age and gender in venous thromboembolism.  J Thromb Thrombolysis. 2009;  , In press
• 69 Roberts L N, Patel R K, Arya R. Venous thromboembolism and ethnicity.  Br J Haematol. 2009;  146(4) 369-383
• 70 Favaloro E J, Orsag I, Bukuya M, McDonald D. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.  Pathology. 2002;  34(4) 348-355
• 71 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.  Blood. 2003;  101(5) 1827-1832
• 72 College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia.  Arch Pathol Lab Med. 2002;  126(11) 1277-1433
• 73 Grody W W, Griffin J H, Taylor A K, Korf B R, Heit J A. ACMG Factor V Leiden Working Group . American College of Medical Genetics consensus statement on factor V Leiden mutation testing.  Genet Med. 2001;  3(2) 139-148
• 74 Nicolaides A N, Breddin H K, Carpenter P European Genetics Foundation et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence.  Int Angiol. 2005;  24(1) 1-26
• 75 Geerts W H, Pineo G F, Heit J A et al.. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3, Suppl) 338S-400S
• 76 Laberge A M, Psaty B M, Hindorff L A, Burke W. Use of factor V Leiden genetic testing in practice and impact on management.  Genet Med. 2009 August 6 (Epub ahead of print); 
• 77 Florell S R, Rodgers III G M. Utilization of testing for activated protein C resistance in a reference laboratory.  Am J Clin Pathol. 1996;  106(2) 248-252
• 78 Somma J, Sussman I I, Rand J H. An evaluation of thrombophilia screening in an urban tertiary care medical center: a “real world” experience.  Am J Clin Pathol. 2006;  126(1) 120-127
• 79 Hindorff L A, Burke W, Laberge A M et al.. Motivating factors for physician ordering of factor V Leiden genetic tests.  Arch Intern Med. 2009;  169(1) 68-74
• 80 Favaloro E J, Lippi G, Adcock D M. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis?.  Semin Thromb Hemost. 2008;  34(7) 612-634
• 81 Bates S M, Greer I A, Hirsh J, Ginsberg J S. Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126(3, Suppl) 627S-644S
• 82 James A H, Abel D E, Brancazio L R. Anticoagulants in pregnancy.  Obstet Gynecol Surv. 2006;  61(1) 59-69, quiz 70–72
• 83 Wong R C, Adelstein S, Gillis D, Favaloro E J. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing.  Semin Thromb Hemost. 2005;  31(1) 39-48
• 84 Wong R CW, Gillis D, Adelstein S et al.. Consensus guidelines on anti-cardiolipin antibody testing and reporting.  Pathology. 2004;  36 63-68
• 85 Wong R C, Favaloro E J, Adelstein S et al.. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting.  Pathology. 2008;  40(1) 58-63
• 86 Wong R C, Favaloro E J. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays.  Semin Thromb Hemost. 2008;  34(4) 361-372
• 87 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4(2) 295-306
• 88 Wilson W A, Gharavi A E, Koike T et al.. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.  Arthritis Rheum. 1999;  42(7) 1309-1311
• 89 Pengo V, Tripodi A, Reber G et al.. Official communication of the scientific and standardization committee on lupus anticoagulant/phospholipid-dependent antibodies: update of the guidelines for lupus anticoagulant detection.  J Thromb Haemost. 2009;  7(10) 1737-1740
• 90 Plebani M, Sanzari M C, Zardo L. Quality control in coagulation testing.  Semin Thromb Hemost. 2008;  34(7) 642-646
• 91 Lippi G, Blanckaert N, Bonini P et al.. Causes, consequences, detection, and prevention of identification errors in laboratory diagnostics.  Clin Chem Lab Med. 2009;  47(2) 143-153
• 92 Gohil R, Peck G, Sharma P. The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls.  Thromb Haemost. 2009;  102(2) 360-370
• 93 Kurnik D, Lubetsky A. Genetic variants and risk for venous thromboembolic events: summing up the evidence.  Thromb Haemost. 2009;  102(2) 183-184